The results from the Dimerix 2017 AGM are available here.
We are very pleased to announce the appointment of a Medical Advisory Board (MAB) to help guide the Company’s DMX-200 clinical program.
The Medical Advisory Board will provide clinical and strategic input into the Company’s lead program, DMX-200 in Chronic Kidney Disease and will provide guidance to the Company as it shapes and progresses its DMX-200 […]
Dimerix (ASX:DXB) is pleased to announce the receipt of a Research and Development (R&D) Tax Incentive refund of $545,771 for the 2016/2017 financial year.
The refund relates to eligible expenditure on the company’s lead program, DMX-200, which has just completed a successful Phase 2a trial, meeting its primary endpoint (safety and tolerability) and showing signals of […]
Read our September 2017 Shareholder Update here
- Welcome letter from CEO Kathy Harrison
- Discussion of phase 2a trial results
- DMX-200 competitor comparisons
- The next steps towards commercialisation
- Introduction to new Non-Executive Director, Hugh Alsop
- Coming events
Dimerix CEO Kathy Harrison is pleased to be speaking alongside a great collection of other biotech companies at the Western Australian AusBiotech Broker Meets Biotech event today.
Date: Wednesday 13 September 2017
Time: 1:00pm arrival for a 1:30pm start
Venue: Parmelia Hilton Perth
14 Mill Street
Dimerix has announced a proposed consolidation of DXB shares.
Full details of the notification are available here.
Dimerix Limited (ASX: DXB), is pleased to announce that manufacturing has been scheduled for later this month to produce the extended release tablet of propagermanium which will be used in the Company’s DMX-200 human pharmacokinetic study and Phase 2b trial in Chronic Kidney Disease.
Read the full release here.